INGELHEIM, Germany & INDIANAPOLIS, US - Thursday, November 7th 2013 [ME NewsWire]

•    Linagliptin showed a statistically significant reduction in blood glucose in adults with Type 2 Diabetes and liver disease

 •    Reduction in blood glucose levels in Asian people aged 65 years or older with Type 2 Diabetes

(BUSINESS WIRE) For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company announce new data that reinforce the efficacy and tolerability of linagliptin in people with Type 2 Diabetes (T2D) and liver disease, as well as Asian people with T2D aged 65 years or older. The data add to a growing body of clinical evidence supporting the use of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor from Boehringer Ingelheim (BI) and Eli Lilly and Company, in a broad range of adults with T2D. The data will be announced on Saturday 9th November during the 2013 International Conference on Diabetes and Metabol ... Read more »